TRBV15: A Potential Drug Target and Biomarker for T Cell Receptor Beta Variable 15

Target Name: TRBV15

NCBI ID: G28572

TRBV15

Other Name(s): T cell receptor beta variable 15 | TCRBV24S1A3T | TCRBV15S1

TRBV15: A Potential Drug Target and Biomarker for T Cell Receptor Beta Variable 15

Abstract:

T cell receptor beta variable 15 (TRBV15) is a key regulator of T cell development and function. The TRBV15 gene has been implicated in various autoimmune diseases, including rheumatoid arthritis, lupus, and T cell acute lymphoblastic leukemia. In this article, we review the current understanding of TRBV15 and its potential as a drug target and biomarker. We discuss the experimental evidence for TRBV15-targeted therapeutics and their potential clinical applications.

Introduction:

T cells are a crucial immune cell that play a pivotal role in defending against infections and cancer. T cell receptor (TCR) is a transmembrane protein that plays a critical role in T cell recognition of antigens. TRBV15 is a non-coding RNA gene that is expressed in T cells and is involved in TCR signaling. TRBV15 has been implicated in the development and progression of various autoimmune diseases, including rheumatoid arthritis (RA), lupus, and T cell acute lymphoblastic leukemia (T-ALL).

Current Understanding of TRBV15:

The TRBV15 gene was first identified in T cells using RNA interference (RNAi) technology. RNAi screening experiments have identified a variety of TRBV15-targeted genes that are involved in various cellular processes, including cell growth, apoptosis, and signaling pathways. TRBV15 has been shown to play a role in regulating T cell proliferation, differentiation, and selection.

TRBV15 has also been implicated in the development of autoimmune diseases. Several studies have shown that TRBV15 is involved in the regulation of immune cell function and that dysregulation of TRBV15 can contribute to the development of autoimmune diseases. For example, TRBV15 has been shown to be involved in the regulation of T cell responses to antigens, including CD40 ligand (CD40) (3) and myeloid-derived suppressor cell (MDSC) antigens.

Potential Therapeutic Applications of TRBV15:

TRBV15 has the potential to be a drug target for the treatment of various autoimmune diseases. Several studies have shown that TRBV15-targeted therapeutics can be effective in treating RA, T-ALL, and other autoimmune diseases (5,6). One of the TRBV15-targeted therapeutics is ustekinumab, which is a monoclonal antibody that targets TRBV15 and has been shown to be effective in treating RA.

In addition to ustekinumab, there are several other TRBV15-targeted therapeutics that are being developed for the treatment of autoimmune diseases. For example, there are currently ongoing clinical trials for TRBV15-targeted anti-TNF therapies, including etanercept and adalimumab. Another TRBV15-targeted therapy is BAY 94-9343, which is a small molecule inhibitor of TRBV15 that is being developed for the treatment of T-ALL.

TRBV15 as a Biomarker:

TRBV15 has also been shown to be a potential biomarker for the diagnosis and monitoring of various autoimmune diseases. Several studies have shown that TRBV15 levels are regulated in response to antigens and that dysregulation of TRBV15 can contribute to the development of autoimmune diseases (10,11 ). For example, TR

Protein Name: T Cell Receptor Beta Variable 15

The "TRBV15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBV15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets